Search Results

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Hancock Jaffe Laboratories, Inc. today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m. ET.

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at 1:00 PM ET.

Eurofins CDMO Alphora Inc., a global Contract Development & Manufacturing Organization and part of the international network of Eurofins laboratories, is pleased to announce a significant expansion of its Drug Product Analytical Services Laboratory, increasing its footprint three-fold.

Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories

Hancock Jaffe Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the VenoValve®

Hancock Jaffe Laboratories, Inc. , today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules.

Hancock Jaffe Laboratories, Inc., a medical device company focused on improving the standard of care in the treatment of venous disease, announced a corporate update which includes a planned corporate rebranding and strategic prioritization of the Company’s development pipeline.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its upsized underwritten public offering of units for gross proceeds of approximately $36 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company.

Mesa Laboratories, Inc. will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 as previously communicated.